Biologics in Spine Surgery: Impact of Postmarketing Safety

Spine

An article recently published in The Spine Journal examines adverse event reporting in studies for biologics use in spine surgery.

According to the study's author Emily Jane Woo, MD, adverse event reports have resulted in safety notifications, label changes and publications covering the safety of biologics. Risks include airway compromise, fatal air embolism and infections following various techniques and procedures.

 

"In light of the rapid development of new biologics, postmarketng surveillance is imperative for ensuring that these products are as safe as possible," Dr. Woo concluded. "By reporting adverse events, surgeons and other healthcare professionals play a key role in improving and refining our understanding of the safety of biologics."

 

More Articles on Spine Surgeons:
Data-Driven Healthcare: Where Spine Surgeons Fit In
Raising & Maintaining Staff Engagement: 6 Spine Surgeon Leaders Discuss
18 Recent Spine Surgery Studies and Findings

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers